Fifteen per cent of patients had a change in their treatment before falling. The average number of drugs per patient was nine per day. In these patients, the rate of prescription of drugs at risk of falling was high (87% for hypotensive treatments and 91% for inducing drowsiness treatments). A very high consumption of diuretics (40%) and benzodiazepines (60%) was observed. The combination of benzodiazepines was found in 16% of patients. Respectively, 24% and 65% of patients had a modification in their hypotensive and inducing drowsiness treatments.

Conclusion The use of drugs that increased the risk of falling was common in our hospital. The recent change in inducing drowsiness treatments seemed to increase the risk of falling.

Pharmaceutical interventions with prescribers on good prescribing practices in the elderly should be strengthened to minimise the use of drugs at risk of falling.

REFERENCES AND/OR ACKNOWLEDGEMENTS
Thanks to the Health Framework.
No conflict of interest.

Additional information

**Abstracts**

**5PSQ-127** DISPENSATION OF FINITE MEDICATION AT DISCHARGE IN THE COMPLEX CHRONIC PATIENT

L. Gómez-Sayago, L. Fito*, MT. Criadó-Illana. Complejo Asistencial de Segovia, Servicio de Farmacia, Segovia, Spain

Background Within the programmes of continuous care of the complex chronic patient (CCP), there are initiatives to improve adherence and continuity of care. Most frequent is dispensing medication upon discharge.

A discharge finite medication (FM) programme for complex chronic diseases (DMCDP) was implemented in the continuity care unit of internal medicine (UCA) in our hospital.

Purpose Evaluate the DMCDFP from our hospital.

Material and methods FM is defined as drugs that the patient doesn’t have and whose estimated duration of treatment is less than 30 days.

A prospective observational study was designed with all patients classified as CCP admitted to the UCA during the first 6 months of 2018, to compare cost and number of doses dispensed (DD) between the community pharmacy (CP) system vs the DMCDP programme.

An Excel database was created. Variables: age, sex, medication dispensed, therapeutic group, indication, duration and days until end of treatment, units dispensed and saved vs CP more adjusted to treatment presentation, estimated cost in CP according to Remedios, cost of hospital dispensation and opportunity cost. All data were analysed with XLS Stat for descriptive statistics.

Tools: history of primary care, electronic prescription, medication bag, informative interview on admission and discharge, medication sheet at discharge, hourly chart, FM in unit doses with posology until the end of treatment and in daily kits dated for medications with variable posology such as descending corticoid patterns. Remedios data base.

Results Sixty-six patients were studied. Age 83 (44–98) years. 94.17% of admissions were reconciled and interviewed on admission and discharge.

All patients had at least seven medical prescriptions: 100% of admissions were reconciled and interviewed on admission and discharge.

Thirty-four (47.2%) patients required FM according to discharge medical prescription to finish initiated hospital treatments for anticoagulation (78%), respiratory infection (ABR) (14%), urinary infection (3%), other infections (4%) and hepatic encephalopathy (1%).

Medication DD avoided were: systemic corticosteroids (59.3%), antibacterial (34.7%) and antithrombotic antihaemorragic (4.7%).

Cost savings in medication for the national health system (88.27%). Pathologies’ greatest savings were AC (78%) and ABR (14%).

The biggest problem on admission and discharge was lack of time.

Conclusion A discharge medication programme led by a hospital pharmacist, reinforces understanding and compliance for each patient, decreases the risk failure due to lack of adherence, knowledge or accessibility problems. In addition, it promotes rational use, since dispensing of the exact units reduces the possibility of future self-medication at home.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

**5PSQ-128** PHARMACOTHERAPEUTIC PROFILE AND RISK OF DRUG-RELATED PROBLEMS AND DRUG INTERACTIONS IN HIV+ PATIENTS OF A HEALTH AREA

M. Onteniente Candela, I. Salas Valverde, M. Gil Candela*, C. Pastor Mondéjar, C. Iniesta Navalón, C. Caballero Requejo, M. García Coronel, E. Urbíeta Sanz. Hospital Universitario Reina Sofia, Hospital Pharmacy, Murcia, Spain

Background The expected lifespan of HIV+ patients has increased dramatically as a result of improved antiretroviral therapy (ART), with the consequent increase in comorbidities and polypharmacy.

Purpose To analyse the profile of comorbidities and polypharmacy in HIV + patients of a Health Area and determine their influence on the risk of presenting drug-related problems (DRPs) and potential clinically significant drug interactions (CSDIs).

Material and methods Retrospective observational study conducted in a Reference Hospital Area that treated 457 HIV + patients with ART. We included all HIV + patients who collected ART in our pharmacy service during a randomly chosen week of March 2018. Variables included in the analysis were: demographics (age, sex) and clinical (viral load (VL), comorbidities) from computerised medical records and pharmacotherapeutic (ART scheme, dispensing data and concomitant treatment) from a management programme (Savac) and application AGORA PLUS®. Patients with ≥2 chronic non-AIDS pathologies were considered pluripathologic and polymedicated if they were prescribed ≥5 non-ART drugs. The risk of DRPs was obtained from the PREDICTOR tool of the Spanish Society of Hospital Pharmacy and CSDIs from the Lexicomp database. Statistical analysis was performed using SPSS v23.0.

Results We included 120 patients (76.7% males), with a mean age of 51.15 ± 9.61 years (59.17% > 50 years’ old). 94.17% had undetectable VL. 54.2% patients were pluripathologic
with a median of three (2–4) comorbidities and 26.7% poly- 
micated with a median of seven (6–9) drugs per patient. 
The most common chronic diseases were: anxiety/depression 
(45.8%), dyslipidaemia (32.5%), hypertension (20.8%) and 
psychiatric disorders (19.2%). Benzodiazepines (32.5%), vita- 
mín D (31.7%), proton-pump inhibitors (22.5%), statins 
(20%), antidepressants (18.3%) and antipsychotics (15%) were 
the most common drugs prescribed.

A total of 55 CSDIs were identified in 41 patients (34.2% 
of patients), of which 78.18% involved ARV drugs. Classes of 
drugs most involved in CSDIs were: pharmacokinetic 
enhancers (40%), protease inhibitors (38.18%), statins 
(25.45%), antipsychotics (25.45%) and antidepressants 
(14.54%). The risk of DRPs was high in 46.7% of patients. 
In statistical analysis (Mann–Whitney U test), the relationship 
between the number of comorbidities and the risk of DRPs 
and CSDIs was statistically significant (p<0.005) in both 
cases.

Conclusion The results of the study demonstrate the aging of 
the HIV +population and the consequences that this entails: 
an increased risk of presenting DRPs as well as the risk of 
CSDIs. Due to this, a meticulous and multidisciplinary 
approach is necessary in this population in order to identify 
the most susceptible patients.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

PSQ-129 BALANCE AND CLASSIFICATION OF 
PHARMACEUTICAL INTERVENTIONS IN A GENERAL 
HOSPITAL OF SPECIALTIES: THE PERSONALISED 
HOSPITAL PHARMACY

1F Gomez-de Rueda, 2F Elósegui Horno, 3B Cancela Díez, 4F Horno Ureña. 1Complejo 
Hospitalario de Jaén, Hospital Pharmacy Clinical Pharmacotherapy, Jaén, Spain; 2Complejo 
Hospitalario de Jaén, Hospital Pharmacy, Jaén, Spain

Background Pharmaceutical care (PC) is the ‘supply of 
medicines with the purpose of achieving concrete results that 
 improve the quality of life of the patient’, being related to 
the global process of prescription through pharmaceutical 
intervention (PI). 

Purpose Analyse the registration data of the PIs carried out in 
a tertiary hospital to avoid adverse effects and health hazards. 

Material and methods Retrospective study of the PIs registered 
between January and August 2018. The PIs were structured in 
three blocks: Block 1: qualitative (method of communication of 
Pis); Block 2: quantitative (active principle, schedules, drugs 
included/not included in the Pharmacotherapeutic Guide 
(PTG) and dose adjustment in paediatric presentations); and 
Block 3: communicative (computer or telephone/personal), 
dose adjustment according to renal and hepatic functions and 
acceptance degree.

Results There were 573 PIs over 12 024 admissions, 72.6% 
in adults and 27.4% in paediatrics. The main method of 
communication was the computer on 408 occasions and tele-
phone/personal in 165, depending on the urgency. The most 
frequent error was schedule (43%), not adjusting for nursing 
shifts, altering the administration of the medication. Those 
of active principle (26%) were due to drugs not included in the 
PTG and of those doses (18%) that were related to paediatric 
presentations. The inadequate form of administration was 
also registered in 6%, being related to the prescription of 
medications not included in the PTG, requiring a complete 
description sensitive to faults in the prescription or transcrip-
tion. Those of low posology (4%) were due to dose adjust-
ment according to renal and hepatic functions, and those of 
high (3%) to shortening of the therapeutic interval. The ‘pharmaceutical performance’ included 63 PIs of therapeutic 
exchange and modified dosages in 29 cases. Acceptance was 
97.5%, performing 98.6% immediately and 1.4% in a range 
of 8 hours. All these problems related to the medication 
were detected and corrected by pharmacists as the intermedi-
ate step between the medical prescription and the nursing 
administration.

Conclusion It has been shown that the review and validation 
of treatments significantly improves therapeutic safety, minimis-
ing the risk to the patient. These results provide quantifiable 
data to measure the activity of the clinical pharmacist, in 
addition to providing data on pharmacotherapeutic quality 
indicators.

REFERENCES AND/OR ACKNOWLEDGEMENTS

Database Pharmacy Unit.

No conflict of interest.

PSQ-130 ANALYSIS OF RITUXIMAB OFF-LABEL USE

1D González Vaquero, 2E Manzano López, 3G Gómez Rodríguez, 4A Martos Rosa, 1Urd 
Romacho, 5P Acosta Robles. 1Agencia Pública Empresarial Sanitaria de Pontevedra, 
Pharmacy Department, El Ejido, Spain; 2Agencia Pública Empresarial Sanitaria Hospital de 
Pontevedra, Internal Medicine Department, El Ejido, Spain

Background Rituximab is a monoclonal antibody indicated in 
Spain in adults with non-Hodgkin’s lymphoma, chronic lym-
phatic leukaemia, rheumatoid arthritis and granulomatosis with 
polyangiitis and microscopic polyangiitis. 

Purpose To evaluate the use of rituximab in a district hospital 
in off-label conditions which did not respond to corticoсте-
roids or immunosuppressants treatment.

Material and methods We carried out a retrospective observa-
tional study of the use of rituximab off-label from its inclu-
sion in the pharmacotherapeutic guide of the hospital in 2009 
until July 2018.

Data collected: number of patients, sex, age, diagnosis, previ-
ous treatment with rituximab, concomitant treatment with 
rituximab, treatment schemes and adverse effects 6 months 
after the start of treatment. Digital clinical history and exter-
nal consultations application were used. Statistical analysis was 
performed with SPSS version 24.

Results Number of patients: 21. Sex: 11 (52.4%) males. 
Mean Age: 53.3 (21–80). Diagnostic groups: six patients 
(28.6%) developed glomerulonephritis, five (23.8%) lupus, 
five (23.8%) vasculitis for cryoglobulins and ANCA positive, 
three (14.3%) myositis and two (9.5%) pemphigus. Treatment 
before rituximab: all patients were treated with prednisone, 
11 (52.4%) with mycophenolate mofetil, 10 (47.6%) with 
azathioprine, 10 (47.6%) with cyclosporine A, six (28.6%) 
with hydroxychloroquine, three (14.3%) methotrexate, two 
(9.5%) with tacrolimus, one (4.8%) with immunoglobulins 
and one (4.8%) with monoclonal antibodies. Concomitant 
treatment with rituximab: all patients had been treated with 
prednisone, five (23.8%) with hydroxychloroquine, five 
(23.8%) with azathioprine, four (19%) with mycophenolate